TITLE

New Investigational Drugs for the Management of Acute Heart Failure Syndromes

AUTHOR(S)
Tamargo, J.; Amoros, I.; Barana, A.; Caballero, R.; Delpon, E.
PUB. DATE
February 2010
SOURCE
Current Medicinal Chemistry;Feb2010, Vol. 17 Issue 4, Special section p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Acute heart failure syndromes (AHFS) enclose a broad spectrum of conditions with different clinical presentations, heart failure history, pathophysiology, prognosis and treatment. AHFS represent a major public health problem because of their high prevalence, high rates of mortality and readmissions and significant healthcare costs, and a therapeutic challenge for the clinicians because management strategies vary markedly. Traditionally used drugs for the treatment of AHFS, including diuretics, vasodilators and positive inotropics, improve clinical signs and symptoms as well as hemodynamics, but present important limitations, as they fail to reduce and may even increase in-hospital and postdischarge mortality, especially in patients with coronary artery disease. Thus, we need new pharmacological agents to not only improve signs and symptoms and cardiac performance, but also improve both short- and long-term outcomes (hospitalizations/ survival). In the last decade, significant efforts have been made to identify new therapeutic targets involved in the genesis/progression of AHFS and to develop new therapeutic strategies that may safely improve outcomes. As a result, several new families of drugs have been developed and are currently studied in experimental models and in Phase II and III clinical trials, in an attempt to define their efficacy and safety profiles as well as their precise role in the treatment of AHFS patients. This review firstly analyzes the main clinical applications and limitations of conventional drugs, and then focuses on the mechanisms of action and effects of recently approved drugs and of new investigational agents on signs, symptoms, hemodynamics and outcomes in AHFS patients.
ACCESSION #
56490834

 

Related Articles

  • How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. Doust, J. A.; Pietrzak, E.; Dobson, A.; Glasziou, P. P. // BMJ: British Medical Journal (International Edition);3/19/2005, Vol. 330 Issue 7492, p625 

    The objective: to assess how well B-type natriuretic peptide (BNP) predicts prognosis in patients with heart failure. Design: Systematic review of studies assessing BNP for prognosis in patients with heart failure or asymptomatic patients. Data sources: Electronic searches of Medline and Embase...

  • The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T. Metra, Marco; Nodari, Savina; Parrinello, Giovanni; Specchia, Claudia; Brentana, Loretta; Rocca, Patrizia; Fracassi, Francesco; Bordonali, Tania; Milani, Patrizia; Danesi, Rossella; Verzura, Giulia; Chiari, Ermanna; Dei Cas, Livio // European Journal of Heart Failure;Aug2007, Vol. 9 Issue 8, p776 

    Abstract: Aims: Brain natriuretic peptide (BNP), NT-proBNP and troponins are useful for the assessment of patients with heart failure. Few data exist about their serial changes and their prognostic value in patients with acute heart failure (AHF). Methods and results: NT-proBNP and troponin-T...

  • QRS and QTc interval prolongation in the prediction of long-term mortality of patients with acute destabilised heart failure. Breidthardt, Tobias; Christ, Michael; Matti, Miriam; Schrafl, Delia; Laule, Kirsten; Noveanu, Markus; Boldanova, Tujana; Klima, Theresia; Hochholzer, Willibald; Perruchoud, André P.; Mueller, Christian // Heart;Sep2007, Vol. 93 Issue 9, p1093 

    Objectives: To quantify the prognostic utility of QRS and QTc interval prolongation in patients presenting with acute destabilised heart failure (ADHF) to the emergency department (ED). Design: Prospective cohort study among patients enrolled in the B-Type Natriuretic Peptide for Acute Shortness...

  • N-terminal brain natriuretic peptide is predictive of death after cardiac transplantation. Gardner, R. S.; Chong, K. S.; Murday, A. J.; Morton, J. J.; McDonagh, T. A. // Heart;Jan2006, Vol. 92 Issue 1, p121 

    The article presents information on a study that evaluates the short term prognostic ability of N-terminal portion of pro-brain natriuretic peptide (NT-proBNP) in patients after cardiac transplantation. Brain natriuretic peptide (BNP) and the NT-proBNP are now well established diagnostic and...

  • B-Type Natriuretic Peptide – A Window to the Heart. Baughman, Kenneth L. // New England Journal of Medicine;7/18/2002, Vol. 347 Issue 3, p158 

    The article presents the author's views about a study on B-type natriuretic peptide. According to the author, the study confirms the importance of B-type natriuretic peptide in the diagnosis of congestive heart failure. The author says that cardiologists and internists may now have a tool which...

  • Alterations in the Natriuretic Hormone System Related to Cardiopulmonary Bypass in Infants with Congestive Heart Failure. Costello, J.M.; Backer, C.L.; Checchia, P.A.; Mavroudis, C.; Seipelt, R.G.; Goodman, D.M. // Pediatric Cardiology;Jul/Aug2004, Vol. 25 Issue 4, p347 

    This study examined changes in the natriuretic hormone system in five infants with congestive heart failure (CHF) due to intracardiac left-to-right shunting who were exposed to cardiopulmonary bypass (CPB) during surgical repair. Plasma concentrations of three hormones [atrial natriuretic...

  • Is N-terminal-pro-B natriuretic peptide a useful parameter in patients with a bidirectional Glenn shunt?  // Cardiology in the Young;May2005 Supplement 2, Vol. 15 Issue S2, p75 

    The article focuses on a study related to plasma levels of N-terminal-pro-B natriuretic peptide (NT-pro-BNP) in children with a BDG correlate with clinical signs of heart failure. All patients had a complete clinical and echocardiographic examination by a pediatric cardiologist. Congestive heart...

  • Examining the uses of BNP testing in the outpatient setting. Harrison, Alex // Patient Care for the Nurse Practitioner;Aug2005, Vol. 8 Issue 8, p2 

    The article focuses on the use of B-natriuretic peptide (BNP) assay in outpatients. Congestive heart failure (CHF) is a prevalent disease whose nonspecific signs and symptoms often present diagnostic and management difficulties. BNP values can be used in several situations, including the...

  • KLINIÄŒKA UPOTREBA NATRIURETSKIH PEPTIDA U SRÄŒANOJ INSUFICIJENCIJI · REVIJALNI PRIKAZ. Bajrić, Mugdim; Baraković, Fahir; Sinanović, Nusret; Mršić, Denis // Acta Medica Saliniana;2008, Vol. 37 Issue 2, p174 

    The most significant discoveries in the area of heart failure are the recognition of natriuretic peptide system and its multiple effects on cardiac structure and function with special effect on its natriuretic and hemodynamic processes. First information's that heart, beside its function as a...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics